STROBE Checklist for "Self-reported food choices before and during COVID-19 lockdown"

	Item No	Recommendation	Reported on Page
Title and abstract Checked	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Abstract, P2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Abstract, P2
Introduction			
Background /rationale Checked	2	Explain the scientific background and rationale for the investigation being reported	Р3
Objectives Checked	3	State specific objectives, including any prespecified hypotheses	Р3
Methods			
Study design Checked	4	Present key elements of study design early in the paper	P4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	P4-5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	P4-5
		(b) For matched studies, give matching criteria and number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	P4-5
Data sources/ measuremen t	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	P4-5
Bias	9	Describe any efforts to address potential sources of bias	P4
Study size	10	Explain how the study size was arrived at	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	P4
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	P4
		(b) Describe any methods used to examine subgroups and interactions	P4
		(c) Explain how missing data were addressed	P4

		(d) If applicable, explain how loss to follow-up was addressed	
		(\underline{e}) Describe any sensitivity analyses	
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	P5
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	P7
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	Report numbers of outcome events or summary measures over time	P7-16
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder- adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	P7-16
Discussion			
Key results	18	Summarise key results with reference to study objectives	P18
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	P18
Interpretatio n	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	P18-19
Generalisabi lity	21	Discuss the generalisability (external validity) of the study results	P18
Other informa			

Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which *Give information separately for exposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.